Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies

RANCHO CORDOVA, Calif., March 30, 2011 /PRNewswire/ —
ThermoGenesis Corp. (Nasdaq:
KOOL), a leading supplier of innovative products and services
that process and store adult stem cells, said today that Nanshan
Memorial Medical Institute (Nanshan), a leading regenerative
medicine company, will be utilizing its AXP® AutoXpress™
(AXP) and BioArchive® Systems used to process and store stem
cells from cord blood in its two stem cell banks in China.
 The Nanshan facilities are located in Biolake, Wuhan City, a
Hubei provincial government supported hi-tech zone specializing in
biotechnology and in Jiuzhou Biotechnology Research Park in Xian
City, Shanxi Province. Nanshan expects to procure over time the
necessary processing and cryopreservation storage capacity to
process and store up to several hundred thousand stem cell units at
each facility.  

Nanshan is a progressive regenerative medicine company that
distributes medical products and has operated multiple, large
healthcare facilities, including hospitals, stem cell banks and
research centers.

Nanshan’s decision to adopt ThermoGenesis’ cord blood
technologies follows a four-year distribution agreement between
ThermoGenesis and Nanshan signed late last year under which Nanshan
will distribute in China and Hong Kong ThermoGenesis’ Res-Q™
60 BMC (Res-Q) System and MXP™ MarrowXpress™ products
used to prepare cell concentrates—including stem
cells—from bone marrow at the point-of-care and in the
laboratory.

“We are delighted to be expanding our relationship with Nanshan
as we continue to implement a key element of our growth strategy by
broadening the geographic reach of our offerings into potential
high growth markets,” said J. Melville Engle, Chairman and Chief
Executive Officer of ThermoGenesis.

“Dr. Lu Daopei, founder and medical director of Nanshan,

‘/>”/>

SOURCE